FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200433148> ?p ?o ?g. }

• W4200433148 endingPage "1245" @default.
• W4200433148 startingPage "1238" @default.
• W4200433148 abstract "High-risk muscle-invasive bladder cancer (MIBC) has a poor prognosis. Old trials showed that external beam radiotherapy (EBRT) after radical cystectomy (RC) decreases the incidence of local recurrences but induces severe toxicity.To evaluate the toxicity and local control rate after adjuvant EBRT after RC delivered with volumetric arc radiotherapy.This is a multicentric phase 2 trial. From August 2014 till October 2020, we treated 72 high-risk MIBC patients with adjuvant EBRT after RC. High-risk MIBC is defined as ≥pT3-MIBC ± lymphovascular invasion, fewer than ten lymph nodes removed, pathological positive lymph nodes, or positive surgical margins.Patients received 50 Gy in 25 fractions with intensity-modulated radiotherapy to the pelvic lymph nodes ± cystectomy bed.The primary outcome is acute toxicity. We report on local relapse-free rate (LRFR), clinical relapse-free survival (CRFS), overall survival (OS), and bladder cancer-specific survival (BCSS).The median follow-up is 18 mo. Forty-two patients (61%) developed acute grade 2 gastrointestinal (GI) toxicity. Four patients (6%) had acute grade 3 GI toxicity. One patient had grade 5 diarrhea and vomiting due to obstruction at 1 mo. Two-year probabilities of developing grade ≥3 and ≥2 GI toxicity were 17% and 76%, respectively. Urinary toxicity, assessed in 17 patients with a neobladder, was acceptable with acute grade 2 and 3 urinary toxicity reported in 53% (N = 9) and 18% (N = 3) of the patients, respectively. The 2-yr LRFR is 83% ± 5% and the 2-yr CRFS rate is 43% with a median CRFS time of 12 mo (95% confidence interval: 3-21 mo). Two-year OS and BCSS are 52% ± 7% and 62% ± 7%, respectively. Shortcomings are the nonrandomized study design and limited follow-up.Adjuvant EBRT after RC can be administered without excessive severe toxicity.In this report, we looked at the incidence of toxicity and local control after adjuvant external beam radiotherapy (EBRT) following radical cystectomy (RC) in high-risk muscle-invasive bladder cancer patients. We found that adjuvant EBRT was feasible and resulted in good local control. We conclude that these data support further enrollment of patients in ongoing trials to evaluate the place of adjuvant EBRT after RC." @default.
• W4200433148 created "2021-12-31" @default.
• W4200433148 creator A5001088157 @default.
• W4200433148 creator A5007857971 @default.
• W4200433148 creator A5021689693 @default.
• W4200433148 creator A5030500303 @default.
• W4200433148 creator A5035515057 @default.
• W4200433148 creator A5036305690 @default.
• W4200433148 creator A5039609539 @default.
• W4200433148 creator A5041605507 @default.
• W4200433148 creator A5043101126 @default.
• W4200433148 creator A5045794019 @default.
• W4200433148 creator A5053682215 @default.
• W4200433148 creator A5055056736 @default.
• W4200433148 creator A5057365802 @default.
• W4200433148 creator A5062837223 @default.
• W4200433148 creator A5073677397 @default.
• W4200433148 creator A5080180751 @default.
• W4200433148 creator A5083566572 @default.
• W4200433148 creator A5088974834 @default.
• W4200433148 date "2022-09-01" @default.
• W4200433148 modified "2023-09-25" @default.
• W4200433148 title "Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial" @default.
• W4200433148 cites W1928587893 @default.
• W4200433148 cites W1968626722 @default.
• W4200433148 cites W1975918912 @default.
• W4200433148 cites W1980835007 @default.
• W4200433148 cites W2043945205 @default.
• W4200433148 cites W2079440108 @default.
• W4200433148 cites W2090241022 @default.
• W4200433148 cites W2109102817 @default.
• W4200433148 cites W2137616140 @default.
• W4200433148 cites W2144535497 @default.
• W4200433148 cites W2152284293 @default.
• W4200433148 cites W2171883057 @default.
• W4200433148 cites W2275996301 @default.
• W4200433148 cites W2332342311 @default.
• W4200433148 cites W2611039607 @default.
• W4200433148 cites W2613354668 @default.
• W4200433148 cites W2770869232 @default.
• W4200433148 cites W2810579527 @default.
• W4200433148 cites W2883475115 @default.
• W4200433148 cites W2959688418 @default.
• W4200433148 cites W3095577486 @default.
• W4200433148 cites W3127419476 @default.
• W4200433148 cites W3138703636 @default.
• W4200433148 cites W3153743354 @default.
• W4200433148 cites W3163995648 @default.
• W4200433148 cites W327557532 @default.
• W4200433148 cites W4253127485 @default.
• W4200433148 doi "https://doi.org/10.1016/j.euf.2021.11.004" @default.
• W4200433148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34893458" @default.
• W4200433148 hasPublicationYear "2022" @default.
• W4200433148 type Work @default.
• W4200433148 citedByCount "6" @default.
• W4200433148 countsByYear W42004331482022 @default.
• W4200433148 countsByYear W42004331482023 @default.
• W4200433148 crossrefType "journal-article" @default.
• W4200433148 hasAuthorship W4200433148A5001088157 @default.
• W4200433148 hasAuthorship W4200433148A5007857971 @default.
• W4200433148 hasAuthorship W4200433148A5021689693 @default.
• W4200433148 hasAuthorship W4200433148A5030500303 @default.
• W4200433148 hasAuthorship W4200433148A5035515057 @default.
• W4200433148 hasAuthorship W4200433148A5036305690 @default.
• W4200433148 hasAuthorship W4200433148A5039609539 @default.
• W4200433148 hasAuthorship W4200433148A5041605507 @default.
• W4200433148 hasAuthorship W4200433148A5043101126 @default.
• W4200433148 hasAuthorship W4200433148A5045794019 @default.
• W4200433148 hasAuthorship W4200433148A5053682215 @default.
• W4200433148 hasAuthorship W4200433148A5055056736 @default.
• W4200433148 hasAuthorship W4200433148A5057365802 @default.
• W4200433148 hasAuthorship W4200433148A5062837223 @default.
• W4200433148 hasAuthorship W4200433148A5073677397 @default.
• W4200433148 hasAuthorship W4200433148A5080180751 @default.
• W4200433148 hasAuthorship W4200433148A5083566572 @default.
• W4200433148 hasAuthorship W4200433148A5088974834 @default.
• W4200433148 hasBestOaLocation W42004331481 @default.
• W4200433148 hasConcept C121608353 @default.
• W4200433148 hasConcept C126322002 @default.
• W4200433148 hasConcept C126894567 @default.
• W4200433148 hasConcept C141071460 @default.
• W4200433148 hasConcept C143998085 @default.
• W4200433148 hasConcept C2775910329 @default.
• W4200433148 hasConcept C2778740770 @default.
• W4200433148 hasConcept C2779013556 @default.
• W4200433148 hasConcept C2780352672 @default.
• W4200433148 hasConcept C29730261 @default.
• W4200433148 hasConcept C509974204 @default.
• W4200433148 hasConcept C71924100 @default.
• W4200433148 hasConcept C90924648 @default.
• W4200433148 hasConceptScore W4200433148C121608353 @default.
• W4200433148 hasConceptScore W4200433148C126322002 @default.
• W4200433148 hasConceptScore W4200433148C126894567 @default.
• W4200433148 hasConceptScore W4200433148C141071460 @default.
• W4200433148 hasConceptScore W4200433148C143998085 @default.
• W4200433148 hasConceptScore W4200433148C2775910329 @default.
• W4200433148 hasConceptScore W4200433148C2778740770 @default.
• W4200433148 hasConceptScore W4200433148C2779013556 @default.

• next